AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteBrefeldin A blocks binding of ADP-ribosylation factor to the Golgi apparatus and inhibits GDP-GTP exchange.
More Information Supplier PageBrefeldin A blocks binding of ADP-ribosylation factor to the Golgi apparatus and inhibits GDP-GTP exchange.
More Information Supplier PageBrefeldin A blocks binding of ADP-ribosylation factor to the Golgi apparatus and inhibits GDP-GTP exchange.
More Information Supplier PageBrefeldin A blocks binding of ADP-ribosylation factor to the Golgi apparatus and inhibits GDP-GTP exchange.
More Information Supplier PageBrequinar is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis.
More Information Supplier PageBrequinar is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis.
More Information Supplier PageBrequinar is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis.
More Information Supplier PageBrequinar is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis.
More Information Supplier PageBretazenil, a benzodiazepine receptor partial agonist, as an adjunct in the prophylactic treatment of OP poisoning.
More Information Supplier PageBretazenil, a benzodiazepine receptor partial agonist, as an adjunct in the prophylactic treatment of OP poisoning.
More Information Supplier PageBretazenil, a benzodiazepine receptor partial agonist, as an adjunct in the prophylactic treatment of OP poisoning.
More Information Supplier PageBrexpiprazole is a novel D2 dopamine partial agonist investigational product currently in clinical trials for the treatment of depression, schizophrenia, and attention deficit hyperactivity disorder (ADHD).
More Information Supplier PageBrexpiprazole is a novel D2 dopamine partial agonist investigational product currently in clinical trials for the treatment of depression, schizophrenia, and attention deficit hyperactivity disorder (ADHD).
More Information Supplier PageBrexpiprazole is a novel D2 dopamine partial agonist investigational product currently in clinical trials for the treatment of depression, schizophrenia, and attention deficit hyperactivity disorder (ADHD).
More Information Supplier PageBriciclib is a benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity.
More Information Supplier PageBriciclib is a benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity.
More Information Supplier PageBriciclib is a benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity.
More Information Supplier PageBrivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
More Information Supplier PageBrivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
More Information Supplier PageBrivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
More Information Supplier PageBrivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
More Information Supplier PageBrivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
More Information Supplier PageBrivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
More Information Supplier PageBrivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
More Information Supplier PageBrivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
More Information Supplier PageBrivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
More Information Supplier PageBrivanib alaninate (BMS-582664) is a dual tyrosine kinase inhibitor of VEGFR and FGFR signaling.
More Information Supplier PageBRL-37344 is a b3-AR (b 3-adrenoceptor) selective agonist with lipolytic activity.
More Information Supplier PageBRL-37344 is a b3-AR (b 3-adrenoceptor) selective agonist with lipolytic activity.
More Information Supplier PageBRL-37344 is a b3-AR (b 3-adrenoceptor) selective agonist with lipolytic activity.
More Information Supplier PageBRL 44408 maleate is a high purity Adrenoceptors antagonist. It increases hippocampal noradrenalin release following systemic administration.
More Information Supplier PageBRL 44408 maleate is a high purity Adrenoceptors antagonist. It increases hippocampal noradrenalin release following systemic administration.
More Information Supplier PageBRL 44408 maleate is a high purity Adrenoceptors antagonist. It increases hippocampal noradrenalin release following systemic administration.
More Information Supplier PageBRL 52537 hydrochloride is a highly selective and potent ??-opioid agonist (Ki = 0.24 nM). 25 times more potent than morphine.
More Information Supplier PageBRL 52537 hydrochloride is a highly selective and potent ??-opioid agonist (Ki = 0.24 nM). 25 times more potent than morphine.
More Information Supplier PageBRL 52537 hydrochloride is a highly selective and potent ??-opioid agonist (Ki = 0.24 nM). 25 times more potent than morphine.
More Information Supplier PageBRL 52537 hydrochloride is a highly selective and potent ??-opioid agonist (Ki = 0.24 nM). 25 times more potent than morphine.
More Information Supplier PageBRL-15572 is a selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.
More Information Supplier PageBRL-15572 is a selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.
More Information Supplier PageBRL-15572 is a selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.
More Information Supplier PageBRL-15572 is a selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.
More Information Supplier PageBRL-15572 is a selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.
More Information Supplier PageBromfenac sodium is a topically selective cyclooxygenase (COX)-2 inhibitor
More Information Supplier PageBromfenac sodium is a topically selective cyclooxygenase (COX)-2 inhibitor
More Information Supplier PageBromfenac sodium is a topically selective cyclooxygenase (COX)-2 inhibitor
More Information Supplier Page
